Postoperative Adjuvant Radiochemotherapy for Patients with Stage III or IV Gastric Cancer

ABSTRACT

first 2 cycles of FOLFOX-4. Chemotherapy schedule was reduced by 25% during the period of the contemporary radiotherapy treatment. Results: All patients except one ended the combined adjuvant treatment. We observed severe hematologic adverse effects only in less than 10% of patients (4 patients); regarding gastrointestinal toxic effects they occurred in 33% of patients and specifically we noted G1-G3 grade toxicity and no G4 toxicity . Disease-free and overall survival at 1, 2, and 3 years was superior to in untreated patients. One to 3-years Median disease–free and overall survival rates were 27 months and 15 months respectively. Conclusions: A combined trial with chemo radiotherapy (CT-RT ) as adjuvant treatment represents an effective approach for patients with resected advanced gastric cancer.